tradingkey.logo
搜尋

Eton Pharmaceuticals Inc

ETON
添加自選
46.420USD
-2.610-5.32%
收盤 07-31 16:00美東報價延遲15分鐘
1.27B總市值
虧損本益比TTM

關於 Eton Pharmaceuticals Inc 公司

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

Eton Pharmaceuticals Inc簡介

公司代碼ETON
公司名稱Eton Pharmaceuticals Inc
上市日期Nov 09, 2018
CEOBrynjelsen (Sean E)
員工數量31
證券類型Ordinary Share
年結日Nov 09
公司地址21925 W Field Pkwy Ste 235
城市DEER PARK
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編60010-7278
電話18477877361
網址https://etonpharma.com/
公司代碼ETON
上市日期Nov 09, 2018
CEOBrynjelsen (Sean E)

Eton Pharmaceuticals Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.06M
+21.54%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--
Ms. Jennifer (Jenn) Adams
Ms. Jennifer (Jenn) Adams
Independent Director
Independent Director
--
--
Mr. David C. Krempa
Mr. David C. Krempa
Chief Business Officer
Chief Business Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.06M
+21.54%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--

常見問題

Eton Pharmaceuticals Inc的前五大股東是誰?

Eton Pharmaceuticals Inc的前五大股東如下:Mr. Sean E. Brynjelsen

有多少機構持有Eton Pharmaceuticals Inc(ETON)的股份?

截至2026Q1,共有235家機構持有Eton Pharmaceuticals Inc的股份,合計持有的股份價值約為15.99M,占公司總股份的58.43% 。與2025Q4相比,機構持股有所增加,增幅為-3678435.00。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有